CellxLife Licenses Mayo Clinic FRα-Targeting Dendritic Cell Vaccine for Ovarian Cancer

CellxLife, a US-based clinical-stage biotechnology company specializing in precision dendritic cell immunotherapies, has entered into an exclusive licensing agreement with Mayo Clinic for a folate receptor alpha (FRα)–targeting dendritic cell cancer vaccine currently under evaluation in 2 phase 2 clinical trials for ovarian cancer. The agreement expands CellxLife's existing proprietary dendritic cell platform, which has previously generated preliminary durability data in pediatric metastatic bone cancer.¹

The licensed vaccine was developed by Keith Knutson, PhD, and Matthew Block, MD, PhD, at Mayo Clinic. It employs a dual immunological mechanism, directing cytotoxic immune activity against FRα-expressing tumor cells while simultaneously inducing Th17 T cells to counteract regulatory T cell (Treg)–mediated immune evasion.

"The FRα-targeting vaccine complements our existing proprietary dendritic cell platform and extends our reach into ovarian cancer—an indication with significant unmet medical need," said Eric von Hofe, PhD, CEO of CellxLife, in a company press release.¹ "With its high recurrence rates after standard of care surgery and chemotherapy, ovarian cancer remains one of the deadliest gynecologic malignancies."

What do the available clinical data show for the licensed dendritic cell vaccine?

In a phase 1 Mayo Clinic study of the FRα-targeting dendritic cell vaccine, approximately 40% of evaluable patients remained cancer-free for at least 10 years, compared to a historical benchmark of approximately 10% in this population, according to companies. The therapy was reported to induce strong tumor-antigen-specific immune responses that correlated with cancer-free survival.

These findings have not been independently verified in the current announcement, and peer-reviewed publication details for this phase 1 dataset were not cited. Two phase 2 trials are currently ongoing, and no interim efficacy or safety data from these trials were disclosed. The vaccine employs a patient-specific manufacturing process in which immune cells are collected from the patient, engineered into a dendritic cell vaccine, and reintroduced to activate targeted anti-tumor responses.¹

How does the vaccine fit within the clinical context and unmet need in recurrent ovarian cancer?

Ovarian cancer is the 5^th leading cause of cancer-related death among women in the United States and carries the highest mortality rate of all gynecologic malignancies, largely because most patients are diagnosed at advanced stage.² Standard first-line treatment consists of cytoreductive surgery followed by platinum-based chemotherapy, with poly (ADP-ribose) polymerase inhibitors used in maintenance settings for patients with BRCA1/2 mutations or homologous recombination deficiency.³ Despite initial response rates exceeding 70% with chemotherapy, the majority of patients with advanced disease relapse within two years, and recurrent ovarian cancer remains largely incurable with available therapies.³ The high recurrence rate and absence of effective immune-based options in this setting represent a well-characterized area of unmet need.

How does the FRα-targeting dendritic cell vaccine work, and how does it differ from conventional cancer vaccines?

FRα is a cell surface protein overexpressed on ovarian cancer cells but present at negligible levels on normal tissue, making it a tumor-selective antigen target.⁴ The licensed vaccine from Mayo Clinic exploits two complementary vulnerabilities by directing cytotoxic T-cell activity against FRα-expressing tumor cells and simultaneously inducing Th17 T cells that counteract Treg-mediated immunosuppression. This mechanistic pairing is intended to overcome the immune evasion that limits the efficacy of many cancer immunotherapies.⁴

This dual mechanism is distinct from the approach of conventional tumor antigen vaccines that address adaptive immune priming without targeting the immunosuppressive tumor microenvironment. Dendritic cell vaccines more broadly have shown modest efficacy in several solid tumor settings, with sipuleucel-T representing the only FDA-approved dendritic cell therapy to date.⁵

What is the significance of this licensing agreement and the available preliminary data to the biopharmaceutical industry?

Several important caveats may apply with this agreement. The 40% ten-year cancer-free survival figure derives from a phase 1 study in which sample sizes are typically small and patient selection may not reflect the broader ovarian cancer population. This figure has not yet been validated in a randomized controlled trial. Historical comparator benchmarks referenced in press releases require careful contextual interpretation, as survival outcomes in ovarian cancer depend heavily on disease stage, BRCA mutation status, and prior treatment exposure. No safety data, patient numbers, or methodological details from the phase 1 study were disclosed at the time of the announcement.

What are the next steps and additional programs in CellxLife's pipeline?

Beyond this program, CellxLife is advancing a phase 2 trial of its proprietary dendritic cell platform in pediatric metastatic bone cancer following phase 1 data suggesting extended survival in a population with historically poor prognosis. A phase 2 basket trial is being planned across glioblastoma, lung, pancreatic, colorectal, and cervical cancers. The company anticipates that the Mayo Clinic FRα-targeting vaccine and its proprietary platform represent mechanistically complementary but distinct technologies. Mayo Clinic retains a financial interest in the licensed technology, with any revenues directed to its not-for-profit mission.¹

References

1. CellxLife. Cellxlife enters into exclusive license agreement for dendritic cell vaccine for ovarian cancer. Published June 16, 2026. Accessed June 17, 2026. https://www.cellxlife.com/
2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763
3. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(2):191-226. doi:10.6004/jnccn.2021.0007
4. Knutson KL, Krco CJ, Erskine CL, et al. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol. 2006;24(26):4254-4261. doi:10.1200/JCO.2006.05.9311
5. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422. doi:10.1056/NEJMoa1001294